Song D, Wilson B, Zhao L, Bhuyan R, Bandyopadhyay M, Lyubarsky A
PLoS One. 2016; 11(11):e0166348.
PMID: 27893831
PMC: 5125596.
DOI: 10.1371/journal.pone.0166348.
Podack E, Munson G
Front Immunol. 2016; 7:464.
PMID: 27857713
PMC: 5093134.
DOI: 10.3389/fimmu.2016.00464.
Patir P, Isik Y, Turk Y, Ugur M, Ceylan C, Gorgun G
Case Rep Hematol. 2015; 2015:908087.
PMID: 26347833
PMC: 4548098.
DOI: 10.1155/2015/908087.
Barata L, Miwa T, Sato S, Kim D, Mohammed I, Song W
J Immunol. 2013; 190(6):2886-95.
PMID: 23390291
PMC: 3594628.
DOI: 10.4049/jimmunol.1202536.
Miwa T, Maldonado M, Zhou L, Yamada K, Gilkeson G, Eisenberg R
Am J Pathol. 2007; 170(4):1258-66.
PMID: 17392165
PMC: 1829459.
DOI: 10.2353/ajpath.2007.060601.
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo.
Liu J, Miwa T, Hilliard B, Chen Y, Lambris J, Wells A
J Exp Med. 2005; 201(4):567-77.
PMID: 15710649
PMC: 2213052.
DOI: 10.1084/jem.20040863.
Deletion of decay-accelerating factor (CD55) exacerbates autoimmune disease development in MRL/lpr mice.
Miwa T, Maldonado M, Zhou L, Sun X, Luo H, Cai D
Am J Pathol. 2002; 161(3):1077-86.
PMID: 12213736
PMC: 1867258.
DOI: 10.1016/S0002-9440(10)64268-X.
Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPI-DAF) and transmembrane DAF gene expression in wild-type and GPI-DAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity.
Miwa T, Sun X, Ohta R, Okada N, Harris C, Morgan B
Immunology. 2001; 104(2):207-14.
PMID: 11683961
PMC: 1783299.
DOI: 10.1046/j.1365-2567.2001.01280.x.
Antibody selection against CD52 produces a paroxysmal nocturnal haemoglobinuria phenotype in human lymphocytes by a novel mechanism.
Taylor V, Sims M, Brett S, Field M
Biochem J. 1997; 322 ( Pt 3):919-25.
PMID: 9148769
PMC: 1218275.
DOI: 10.1042/bj3220919.
Paroxysmal nocturnal hemoglobinuria and the glycosylphosphatidylinositol anchor.
Yeh E, Rosse W
J Clin Invest. 1994; 93(6):2305-10.
PMID: 8200963
PMC: 294434.
DOI: 10.1172/JCI117234.
Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes. Studies on C9 binding and incorporation into high molecular weight complexes.
Rosenfeld S, JENKINS Jr D, Leddy J
J Exp Med. 1986; 164(4):981-97.
PMID: 3760783
PMC: 2188431.
DOI: 10.1084/jem.164.4.981.
Deficiency of lymphocyte function-associated antigen 3 (LFA-3) in paroxysmal nocturnal hemoglobinuria. Functional correlates and evidence for a phosphatidylinositol membrane anchor.
Selvaraj P, Dustin M, Silber R, Low M, Springer T
J Exp Med. 1987; 166(4):1011-25.
PMID: 3309123
PMC: 2188732.
DOI: 10.1084/jem.166.4.1011.
Retrovirus-induced feline pure red cell aplasia. Hematopoietic progenitors are infected with feline leukemia virus and erythroid burst-forming cells are uniquely sensitive to heterologous complement.
Abkowitz J, Holly R, Grant C
J Clin Invest. 1987; 80(4):1056-63.
PMID: 2821071
PMC: 442346.
DOI: 10.1172/JCI113160.
Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Holguin M, Fredrick L, Bernshaw N, Wilcox L, Parker C
J Clin Invest. 1989; 84(1):7-17.
PMID: 2738160
PMC: 303946.
DOI: 10.1172/JCI114172.
Amelioration of lytic abnormalities of paroxysmal nocturnal hemoglobinuria with decay-accelerating factor.
Medof M, Kinoshita T, Silber R, NUSSENZWEIG V
Proc Natl Acad Sci U S A. 1985; 82(9):2980-4.
PMID: 2581259
PMC: 397690.
DOI: 10.1073/pnas.82.9.2980.
Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria.
Holguin M, Wilcox L, Bernshaw N, Rosse W, Parker C
J Clin Invest. 1989; 84(5):1387-94.
PMID: 2478585
PMC: 304000.
DOI: 10.1172/JCI114311.
Normal polymorphic variations and transcription of the decay accelerating factor gene in paroxysmal nocturnal hemoglobinuria cells.
Stafford H, Tykocinski M, Lublin D, Holers V, Rosse W, Atkinson J
Proc Natl Acad Sci U S A. 1988; 85(3):880-4.
PMID: 2448783
PMC: 279660.
DOI: 10.1073/pnas.85.3.880.
Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.
Medof M, Gottlieb A, Kinoshita T, Hall S, Silber R, NUSSENZWEIG V
J Clin Invest. 1987; 80(1):165-74.
PMID: 2439544
PMC: 442215.
DOI: 10.1172/JCI113043.
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids.
Medof M, Walter E, Rutgers J, Knowles D, NUSSENZWEIG V
J Exp Med. 1987; 165(3):848-64.
PMID: 2434600
PMC: 2188295.
DOI: 10.1084/jem.165.3.848.
Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.
Devine D, Siegel R, Rosse W
J Clin Invest. 1987; 79(1):131-7.
PMID: 2432087
PMC: 424006.
DOI: 10.1172/JCI112773.